CERTIFICATE OF FINISHED PRODUCT ANALYSIS

Product Name:	**Enoxacan-20 Injection (Enoxaparin Sodium Injection IP 20mg/0.2ml)**		
Batch No.	26PI118A	**A.R. No.**	FP260443
Batch Size	3010 PFS	**Sample Quantity**	60 PFS
Mfg. Date	09/2026	**Date of Testing**	30/09/2026
Exp. Date	08/2028	**Date of Release**	15/10/2026
Reference Batch No	26PI118	**MFG. Lic. No.**	N-MB/2023/263

Sr. No.	Test	Specification	Observation
1.	**Description**	Clear and colorless liquid filled in glass prefilled syringe.	Clear and colorless liquid filled in glass prefilled syringe.
2.	**Identification**		
	A. By Chemical	A creamy white precipitate should be formed.	Complies
	B. By UV	Show absorption maxima at 231 nm.	Complies
	C. By Chemical	Complies with the test for sodium	Complies
3.	**pH**	5.5 to 7.5	6.55
4.	**Benzyl Alcohol (if Present)**	1.35 to 1.65%	Absent
5.	**Free Sulphate**	NMT 0.12 %	Not Detected
6.	**Extractable Volume**	NLT 0.2 ml	0.2 ml
7.	**Bacterial Endotoxins**	NMT 0.01 Endotoxin unit per unit of anti-factor $X_a$activityin Anti-factor X_a IU.	Less than 0.01 Endotoxin unit per unit of anti-factor $X_a$activityin Anti-factor X_a IU.
8.	**Particulate Matter**	Injections that are solutions, when examined under suitable conditions of visibility, are clear and practically free from particles that can be observed on visual inspection by the unaided eye.	Complies
9.	**Sterility**	Should be Sterile	Sterile

CERTIFICATE OF FINISHED PRODUCT ANALYSIS

Product Name:	**Enoxacan-20 Injection (Enoxaparin Sodium Injection IP 20mg/0.2ml)**		
Batch No.	26PI118A	**A.R. No.**	FP260443
Batch Size	3010 PFS	**Sample Quantity**	60 PFS
Mfg. Date	09/2026	**Date of Testing**	30/09/2026
Exp. Date	08/2028	**Date of Release**	15/10/2026
Reference Batch No	26PI118	**MFG. Lic. No.**	N-MB/2023/263

10.	**Assay: Each pre-filled syringe contains:** **Enoxaparin Sodium IP 20 mg** **(Equivalent to 2000 IU Anit-factor Xa units)**	**Anti factor X_a activity** 1800 IU to 2200 IU (90.0 to 110.0%) **Anti factor II_a activity** NLT 2000 and NMT 3500 anti-factor II_a IU per ml. **Anti-factor X_a to anti-factor II_a ratio** NLT 3.3 and NMT 5.3	2073.9 IU (103.70%) 2600.34 IU per ml 3.99

Remark: The sample is complies as per IP /BP/ USP/IH specification.

	Prepared By	Checked By	Approved By
Sign/Date	15/10/2026	15/10/2026	15/10/2026
Name	**Diksha Saini**	**Vinay Kumar**	**Bhupinder Navet**
Designation	**Officer QC**	**Sr.Executive-QC**	**Head-QC**

Name: Bhupinder Navet
Designation: Head QC
Qualification: M. Pharma
Registration No: 12-DVI-103
Pt BD Sharma University of Health Sciences, Rohtak